PROSTAT-SPESİFİK MEMBRAN ANTİGEN MENENGİOM TEDAVİSİNDE YER ALABİLİR Mİ?

Abstract

Amaç Tümör oluşumunda ve ayırıcı tanısında tümör anjiogenezi önemli bir unsur ve değerli bir göstergedir. Menengiomlar vasküleritesi yüksek tümörler olması nedeni ile bu çalışmada, farklı tedavi protokollerinin geliştirilebilmesi açısından menengiomlarda immunohistokimyasal yöntemlerle prostat-spesifik membran antijen (PSMA) salınımının değerlendirilmesi amaçlanmıştır. Gereç ve Yöntem Kliniğimizde opere edilerek Derece I (n=32), Derece II (n=6) ve Derece III (n=10) menengiom tanısı almış 48 hastadan alınmış olan doku örneklerinde PSMA antikorları immunohistokimyasal metod ile incelendi. Tümör dokusundaki PSMA boyanma yoğunluğu ve yüzdesi incelendi. Tümör epitelinde tümör ve tümör-dışı dokuda PSMA salınımına göre vasküler salınım ve yoğunluk skoru analiz edildi. Bulgular Farklı derecelerdeki menengiom preparatlarında yapılan immunohistokimyasal analizler tümör epitelinde ve stromasında PSMA salınım ve yoğunluk skorları arasında istatistiksel olarak anlamlı farklılık olmadığını gösterdi (p>0.05). Sonuç Agresif seyreden, rezeke edilemeyen menegiomlarda anjiogeneziste rol alan bazı moleküler biomarkerlar önem kazanmaktadır. Her ne kadar PSMA açısından anlamlı sonuçlar elde edilmemiş olsa da moleküler ve genetik teknikler geliştikçe tümör biyolojisinin ortaya konup potansiyel hedeflerin belirlenmesi yeni tedavi yolları açacaktır.

Keywords

• menengiom
• antijen
• prostat-spesifik membran
• anjiogenez

CAN PROSTATE-SPECIFIC MEMBRANE ANTIGENE TAKE PART IN MENENGIOMA TREATMENT?

Abstract

Objective In tumor development, tumor angiogenesis is an essential component, and a valuable marker in the differantial diagnosis of brain tumors. As menengiomas are highly vascular tumors in this study, we aimed to evaluate the expression of prostate-spesific membrane antigen (PSMA) in menengiomas by immunohistochemistry method to determine different target therapies. Material and Method Pathologic specimens with the diagnosis Grade I (n=32), Grade II (n=6) ve Grade III (n=10) of 48 patients operated for menengioma in our clinic, were evaluated for PSMA-antibody via immunohistochemical method. PSMA staining intensities in tumor tissue and tumor epithelium were analyzed. Vascular expression in tumoral and extratumoral stroma, and intensity score, according to PSMA expression, in tumoral epithelium were analyzed. Results Immunohistochemical analyses of different grade menengioma specimens showed no statistically significant differences between PSMA expression and PSMA staining intensities in tumor tissue and tumor epithelium (p>0.05). Conclusion Some molecular biomarkers, that take part in angiogenesis of agressive and unresectable menengiomas come into prominence. Although no significant results were achieved in terms of PSMA, as the molecular and genetic techniques progress, tumor biology manifestation and determination of potential targets will lead to new treatment procedures.

Keywords

• menengioma
• antigen
• prostate-spesific membrane
• angiogenesis

References

1. 1. Martinez NL, Khanna O, Farrell CJ. A narrative review of targeted therapy in meningioma, pituitary adenoma, and craniophargyngioma of the skull base. Chin Clin Oncol 2020;9(6):75.
2. 2. Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS Statistical report: primary brian and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol 2019;21:v1-v100.
3. 3. Matsuda M, Ishikawa E, Yamamoto T, Hatano K, Joraku A, Lizumi Y, Masuda Y, Nishiyama H, Matsumara A. Potential use of prostate spesific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with ⁸⁹Zr-Df-IAB2M anti-PSMA minibody. J of Neuro-Oncology 2018;138:581-589.
4. 4. Akhtar NH, Pail O, saran A, et al. Prostate-spesific membrane antigen based therapeutics. Advanced in Urology. 2012;2012:973820. doi: 10.1155/2012/973820.
5. 5. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987;7:927–35.
6. 6. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor- associated neovasculature. Cancer Res. 1999;59:3192–8.
7. 7. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, et al. Monoclonal antibodies to the extracellular domain of prostate- specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 1997;57:3629–34.
8. 8. Kiess AP, Banerjee SR, Mease RC, Rowe SP, Rao A, Foss CA, Chen Y, Yang X, Cho SY, Nimmagadda S, Pomper MG. Prostate spesific membrane antigen as a target for cancer imaging and therapy. Quart J Nucl Med Mol Imaging 2015;59:241-268.

9. 9. Pandit-Taskar N, O’Donoghue JA, Ruan S, Lyanshchenko SK,- Carrasquillo JA, Heller G, Martinez DF, Cheal SM, Lewis JS, Fleisher M, Keppler JS, Reiter RE et al. First in human imaging with ⁸⁹Zr-Df-IAB2M Anti-PSMA minibody in patients with metastatic prostate cancer: pharmacokinetics, biodistribution, dosimetry, and lesion uptake. J Nucl Med 2016;57:1858-1864.
10. 10. Nomura N, Pastorino S, Jiang P, et al. Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastasis. Caner Cell International. 2014;14.
11. 11. Wernicke AG, Edgar MA, Lavi E, et al. Prostate Specific Membrane Antigen as a potential Novel Vascular Target for Treatment of Glioblastoma Multiforme. Aarchives of Pathology and Laboratory Medicine. 2011;135:1486–9.
12. 12. Mahzouni P, Shavakhi M. Prostate-spesific membrane antigen expression in neovasculature of glioblastoma multiforme. Adv Biomed Res. 2019;8:18.
13. 13. Wernicke AG, Varma S, Greenwood EA et al Prostate‐specific membrane antigen expression in tumor‐associated vasculature of breast cancers. Apmis 2014;122(6):482-9.
14. 14. Wernicke AG, Kim S, Liu H, Bander NH, Pirog EC Prostate- specific membrane antigen (PSMA) expression in the neovasculature of gynecologic malignancies: implications for PSMA-targeted therapy. Immunohistochemistry & Molecular Morphology. 2017;25(4):271-6.
15. 15. Barresi V. Angiogenesis in meningiomas. Brain Tumor Pathol 2011;28:99-106.
16. 16. Chang SS, Keefe DSO, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-spesific membrane antigen is produced in tumor-associated neovasculature. Clin cancwer Res. 1999;5(10):2674-81.
17. 17. Tubre T, Hacking S, Alexander A, et al. Prostate-Specific Membrane Antigen Expression in Meningioma: A Promising Theranostic Target. J neuropathol Exp Neurol 2022;81(12):1008- 1017.
18. 18. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga] gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013;24:486–495.
19. 19. Mettler F, Guiberteau M. Essentials of nuclear medicine and molecular imaging. 7th ed. Philadelphia, PA: Elsevier, 2019.
20. 20. Gupta N, Verma R, Belho ES. Prostate-Specific Membrane Antigen-Avid Meningioma Detected in 68Ga-Prostate-Specific Membrane Antigen PET/CT. Clin Nucl Med 2020; 45(9): 692- 693.
21. 21. Haemels M, jentjens S, Cleeren F, et al. All that glitters is not prostate cancer: incidental finding of PSMA-avid meningioma. Hell J Nucl Med 2020;23(1):79-80.
22. 22. Jiang JY, Yip JWL, Kang C, et al. Incidental prostate-specific membrane antigen-avid meningioma detected on 68Ga-prostate-specific membrane antigen PET/CT. Radiol Case Rep 2021;16(11):3422-3425.
23. 23. Junqueira MZ, Rocha NH, Sapienza MT. 68Ga-Prostate-Specific Membrane Antigen PET/CT Uptake in Intraventricular Meningioma in the Choroid Plexus. Clin Nuck Med 2021;46(1):58- 59.
24. 24. de Galiza Barbosa F, Queiroz MA, Nunes RF, et al. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imag 2020;20: 23.
25. 25. Bilgin R, Ergül N, Çermik TF. Incidental meningioma mimicking metastasis of prostate adenocarcinoma in ⁶⁸Ga-labeled PSMA PET/CT. Clinical Nuclear Medicine 2016;41(12):956-958.
26. 26. Meewes C., Bohuslavizki K. H., Krisch B., Held-Feindt J., Henze E., Clausen M. Molecular biologic and scintigraphic analyses of somatostatin receptor-negative meningiomas. Journal of Nuclear Medicine. 2001;42(9):1338–1345.